MENU

EPFZ Microrobots: Magnetic Blood Clot Dissolution Performance

RTS(Radio Télévision Suisse) Switzerland
Overview
EPFZ has developed magnetic microrobots that dissolve blood clots six times faster than medication alone in artificial vessel tests. By utilizing a rotating magnetic field to navigate and generate flow, these devices address the challenge of delivering thrombolytic agents to obstructed vascular sites.
In Depth

Key Findings

In tests using artificial blood vessels and porcine blood clots, microrobots developed by EPFZ dissolved clots six times faster than treatments using medication alone. Further trials conducted on living pigs demonstrated increased efficacy; after 30 minutes, the surface area of the irrigated vasculature was twice as large compared to treatments administered without the microrobots.

Technical Details

The microrobots measure approximately eight micrometers in size. They are constructed from a biocompatible sugar polymer gel integrated with magnetic iron oxide nanoparticles. These nanoparticles are not distributed uniformly but are instead clustered along the longitudinal axis of the robot.

Navigation and propulsion are achieved through the following mechanisms:

  • Control: The robots respond to an externally generated rotating magnetic field, allowing for precise steering through blood vessels.
  • Movement: The devices move along the vascular wall using a motion described as similar to a gymnast performing “flips.”
  • Drug Delivery: This specific movement generates a current that actively transports medication toward the target blood clot.

Background and Context

The technology addresses a critical limitation in treating vascular occlusions. While medications to dissolve clots exist, they often fail to reach the site of action in a timely manner because the obstruction itself halts the blood circulation necessary for drug transport. Such occlusions can lead to severe medical emergencies, including stroke, myocardial infarction, or pulmonary embolism, depending on the affected vessel.

Significance and Outlook

EPFZ has filed a patent application for this invention. However, the technology is not yet ready for clinical use in humans suffering from acute vascular obstruction. The research team intends to conduct further animal studies to evaluate long-term safety and test the robots in specific medical models, such as heart attack simulations. The corresponding scientific article has not yet been published and remains subject to independent peer review.

Source: https://www.rts.ch/info/sciences-tech/2026/article/epfz-des-microrobots-pour-dissoudre-les-caillots-sanguins-29410851.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC